Barbara Gayle Duncan Insider Trading $DOVP Euthymics Bioscience, Inc.
Get free email notifications about insider trading for Barbara Gayle Duncan.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of Barbara Gayle Duncan. Barbara Gayle Duncan is Director in IMMUNOMEDICS INC ($IMMU) and Director in Innoviva, Inc. ($THRX) and CEO in Euthymics Bioscience Inc ($DOVP) and Director in Euthymics Bioscience Inc ($DOVP) and President and CFO in Euthymics Bioscience Inc ($DOVP) and Director in MEDGENICS, INC. ($MDGN) and Chief Accounting Officer in INTERCEPT PHARMACEUTICALS INC ($ICPT) and Chief Financial Officer in INTERCEPT PHARMACEUTICALS INC ($ICPT) and Director in Atea Pharmaceuticals, Inc. ($AVIR) and Director in Adaptimmune Therapeutics PLC ($ADAP) and Director in Ovid Therapeutics Inc. ($OVID) and Director in Jounce Therapeutics, Inc. ($JNCE) and Director in Fusion Pharmaceuticals Inc. ($FUSN).
Barbara Gayle Duncan in Euthymics Bioscience, Inc.
Industry: PHARMACEUTICAL PREPARATIONS [2834]
Position of Barbara Gayle Duncan: Director, CEO, President and CFO
Holdings: 0 shares
Latest Transaction: May 20 2008
Last 4 weeks trend: HOLD
Last 3 months trend: HOLD
Latest Insider Trading Transactions of Barbara Gayle Duncan in Euthymics Bioscience, Inc.
| 1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
|---|---|---|---|---|---|---|---|
| No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Sentiment: All, ADAP, GNMX, AVIR, DOVP, FUSN, IMMU, THRX, ICPT, JNCE, OVID
Page: 1
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| May 20 2008 | DOVP | Euthymics Bioscien ... | Duncan Barbara Gayle | Director | Option Exercise | A | 0.00 | 550,000 | 0 | 3,778,500 | |
| May 20 2008 | DOVP | Euthymics Bioscien ... | Duncan Barbara Gayle | Director | Option Exercise | A | 0.00 | 550,000 | 0 | 3,778,500 | |
| May 20 2008 | DOVP | Euthymics Bioscien ... | Duncan Barbara Gayle | Director | Option Exercise | A | 0.00 | 550,000 | 0 | 3,778,500 | |
| May 20 2008 | DOVP | Euthymics Bioscien ... | Duncan Barbara Gayle | Director | Option Exercise | A | 0.00 | 698,500 | 0 | 3,778,500 | |
| May 20 2008 | DOVP | Euthymics Bioscien ... | Duncan Barbara Gayle | Director | Option Exercise | A | 0.00 | 724,500 | 0 | 3,778,500 | |
| May 20 2008 | DOVP | Euthymics Bioscien ... | Duncan Barbara Gayle | Director | Option Exercise | A | 0.00 | 705,500 | 0 | 3,778,500 | |
| May 20 2008 | DOVP | Euthymics Bioscien ... | Duncan Barbara Gayle | Director | Option Exercise | D | 0.00 | 5,830,709 | 0 | 3,778,500 | |
| Aug 13 2007 | DOVP | Euthymics Bioscien ... | Duncan Barbara Gayle | CEO | Option Exercise | A | 0.33 | 5,031,209 | 1,660,299 | 5,830,709 | |
| Jan 23 2007 | DOVP | Euthymics Bioscien ... | Duncan Barbara Gayle | President and CFO | Option Exercise | A | 0.39 | 75,000 | 29,250 | 799,500 | |
| Jul 05 2006 | DOVP | Euthymics Bioscien ... | Duncan Barbara Gayle | President and CFO | Option Exercise | A | 2.12 | 350,000 | 742,000 | 724,500 |
Page: 1